Background: After acute myocardial infarction (AMI), inflammatory processes promote tissue remodeling at the infarct site. Procollagen III amino-terminal propeptide (PIIINP) is a circulating biomarker of type III collagen synthesis that has been shown to be associated with changes in left ventricular ejection fraction (LVEF) and predicts the occurrence of heart failure after AMI. We hypothesize that sleep-disordered breathing (SDB) promotes inflammation and myocardial fibrosis, leading to reduced myocardial salvage. Therefore, in patients with first-time AMI successfully treated with percutaneous coronary intervention (PCI), we aimed to investigate whether circulating levels of high-sensitivity C-reactive protein (hs-CRP) and PIIINP are elevated in patients with SDB compared to patients without SDB. Methods and Results: This cross-sectional analysis included a total of 88 eligible patients with first AMI and PCI pooled from two prospective studies and stratified according to the apnea–hypopnea index (AHI, with SDB: AHI ≥ 15 h−1). We analyzed circulating levels of hs-CRP and PIIINP 3–5 days after PCI. Patients with SDB had significantly higher levels of hs-CRP (18.3 mg/L [95% CI, 8.0–42.6] vs. 5.8 mg/L [95% CI, 4.2–19.8], p = 0.002) and PIIINP (0.49 U/mL [95% CI, 0.40–0.60] vs. 0.33 U/mL [95% CI, 0.28–0.43], p < 0.001). In a multivariable linear regression model accounting for important clinical confounders, SDB significantly predicted circulating levels of hs-CRP (p = 0.028). Similarly, only SDB was independently associated with PIIINP (p < 0.001). Only obstructive but not central AHI correlated with circulating levels of hs-CRP (p = 0.012) and PIIINP (p = 0.006) levels. Conclusions: The presence of obstructive SDB after AMI was independently associated with increased circulating levels of hs-CRP and PIIINP. Our results emphasize the important role of SDB as a common comorbidity and indicate increased inflammation and myocardial fibrosis in these patients.
Background: Coronary collateral flow in angiography has been linked with lower mortality rates in patients with coronary artery disease. However, the relevance of the underlying mechanism is sparse. Therefore, we tested the hypothesis that in patients with acute myocardial infarction (AMI), relevant coronary collateral flow is associated with more salvaged myocardium and lower risk of developing heart failure. Methods and Results: Patients with first AMI who received a percutaneous coronary intervention within 24 h after symptom onset were classified visually by assigning a Cohen–Rentrop Score (CRS) ranging between 0 (no collaterals) and 3 (complete retrograde filling of the occluded vessel). All 36 patients included in the analysis underwent cardiac magnetic resonance examination within 3 to 5 days after myocardial infarction and after 12 weeks. Patients with relevant collateral flow (CRS 2–3) to the infarct-related artery had significantly smaller final infarct size compared to those without (7 ± 4% vs. 20 ± 12%, p < 0.001). In addition, both groups showed improvement in left ventricular ejection fraction early after AMI, whereas the recovery was greater in CRS 2–3 (+8 ± 5% vs. +3 ± 5%, p = 0.015). Conclusion: In patients with first AMI, relevant collateral flow to the infarct-related artery was associated with more salvaged myocardium at 12 weeks, translating into greater improvement of systolic left ventricular function. The protective effect of coronary collaterals and the variance of infarct location should be further investigated in larger studies.
Sleep-disordered breathing (SDB) represents a modifiable treatment target in patients with heart failure (HF). Despite the evolution of positive airway pressure (PAP) therapy over the past several decades, randomised controlled trials have not demonstrated a consistent benefit in reducing mortality or hospital admissions related to HF. As a result, the use of PAP therapy has been primarily limited to symptom control of SDB. However, recent trials suggest that PAP therapy is safer than previously perceived and underscore an urgent need for a phenotype-based, individualised treatment approach. Stratifying patients according to sleep apnoea phenotypes or characteristic clinical clusters may enhance the identification of individuals most likely to respond favourably to PAP therapy in terms of clinical outcomes. This narrative review provides an outline of the current evidence regarding the use of PAP therapy in patients with SDB across the spectrum of HF phenotypes.
Background: In patients with acute myocardial infarction, altered cardiac repolarisation has been linked to ventricular fibrillation and major adverse cardiac events. Treatment of sleep disordered breathing early after acute myocardial infarction may normalise the ventricular ectopic substrate. Therefore, the aim of this ancillary analysis was to assess the effect of adaptive servoventilation (ASV) on cardiac repolarisation. Methods: This analysis included 42 participants from the prospective multicentre randomised trial TEAM-ASV I. 22 were randomised to early treatment with ASV in addition to standard care, and 20 to standard care only. Cardiac repolarisation was assessed by means of T-peak-to-end- (TpTe c ) and QT c - intervals and TpTe/QT-ratios derived from 12-lead ECG before and 4 and 12 weeks after percutaneous coronary intervention. Results: The population was predominantly male (79%), obese (mean± sd body mass index 31±6 kg·m −2 ), had severe sleep disordered breathing with an apnoea–hypopnoea index of 34±18 events·h −1 and ASV was initiated within 2.6±1 days. After 4 weeks, QT c significantly decreased in the ASV group compared to the control group (−5.8% versus −1.2%, p=0.041). A similar trend was observed with respect to TpTe c (−18.0% versus −6.8%, p=0.119) and TpTe/QT (−17.6% versus −6.6%, p=0.252). After 12 weeks, the decrease in repolarisation times was similar between the groups. (QT c −7.6% versus −4.5%, p=0.400; TpTe c −19.3% versus −18.8%, p=0.400; TpTe/QT −9.7 versus −13.0, p=0.652). Conclusion: In patients with first acute myocardial infarction and sleep disordered breathing, early treatment with ASV reduced cardiac repolarisation after 4 weeks, but not after 12 weeks. Thus, ASV may contribute to preventing ventricular arrhythmias in the vulnerable early phase after acute myocardial infarction.
Study objectives: In patients with acute myocardial infarction (AMI), early use of minute-ventilation triggered adaptive servo-ventilation (ASVmv) for sleep-disordered breathing has been proposed as a therapeutic intervention to reduce infarct expansion. This study aims to assess the efficacy of ASVmv in modulating nocturnal hypoxemic burden and evaluate its association with infarct size. Methods: This ancillary analysis of the multicenter, randomized, open-label TEAM-ASV I trial included patients with first-time AMI and sleep-disordered breathing, defined by an apnea-hypopnea index ≥ 15 events h−1 assessed with polygraphy. Infarct size was quantified via cardiac magnetic resonance imaging. Nocturnal hypoxemic burden was quantified by the time in bed spent with oxygen saturation below 90% (T90) and further decomposed into desaturation-related components (T90desaturation) and non-specific drifts (T90non-specific). Results: Thirty-five patients with infarct size 15.5 ± 6.9% of left ventricular mass were randomized to early ASVmv treatment in addition to standard care of AMI (n = 16) and standard care alone (control, n = 19). Compared with baseline, all components of hypoxemic burden, T90 (9.25% [1.34–16.32] vs. 0.03% [0.00–1.72; p = .003]), T90desaturation (0.72% [0.49–7.97] vs. 0.00% [0.00–0.06]; p < .001), and T90non-specific (4.75% [0.38–10.30] vs. 0.00% [0.00–1.73]; p < .001) were significantly reduced during the ASVmv treatment initiation night. After 12 weeks, ASVmv treatment showed lower median T90desaturation compared to the control group (ASVmv: 0.10% [0.00–0.40] vs. control: 0.40% [0.22–1.80]; p = .020) but not T90non-specific. T90 (rs = 0.437, p = .023) and its component, T90non-specific, were both associated with infarct size (rs = 0.424; p = .028). Conclusions: ASVmv treatment suppresses the sleep apnea-related nocturnal hypoxemic burden following AMI. Higher T90, particularly non-specific drifts in SpO₂, were associated with larger infarct size. These findings are exploratory and should be regarded as hypothesis generating. Clinical trial registration: NCT02093377.
(1) Background: Early treatment of sleep-disordered breathing (SDB) with adaptive servo-ventilation (ASV) after acute myocardial infarction (AMI) has been shown to improve myocardial salvage. This analysis evaluates nocturnal electrocardiogram (ECG) Holter data, derived from polygraphy in a randomised clinical trial (NCT02093377), to assess the occurrence of nocturnal cardiac arrhythmias in patients with SDB and to explore the effect of ASV therapy. (2) Methods: In the TEAM-ASV I trial, patients were stratified by the presence/absence of SDB, defined by an apnoea–hypopnoea index (AHI) ≥15 events/h assessed with polygraphy. Those with SDB were subsequently randomised to receive ASV in addition to standard AMI care. Guideline-conforming semi-automated ECG analysis of nocturnal cardiac arrhythmias was conducted via Holter–ECG software (custo diagnostic, version 5.4). (3) Results: Patients with SDB had an increased incidence of non-sustained ventricular tachycardia (NSVT) (SDB: n = 8 (16%) vs. no SDB: n = 1 (2%); p = 0.024) and premature atrial contractions (PAC) (SDB: 1.2/h [0.3, 3.4] vs. no SDB: 0.3/h [0.1, 1.2]; p = 0.017). In patients with SDB who were randomised to ASV treatment early after AMI, we found no reduction in cardiac arrhythmias when ASV was added to standard care. (4) Conclusions: After AMI, SDB was linked to increased NSVT and PAC. ASV treatment demonstrated neither a harmful nor a beneficial effect on the occurrence of nocturnal cardiac arrhythmias. Further trials are warranted to confirm these findings.